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One-third of ER-positive breast cancer patients who initially respond to endocrine therapy 
become resistant to treatment. Such treatment failure is associated with poor prognosis and 
remains an area of unmet clinical need.  Here we identify a specific post-translational 
modification that occurs during endocrine resistance and which results in tumour 
susceptibility to the apoptosis inducer TNF-Related Apoptosis-Inducing Ligand (TRAIL). This 
potentially offers a novel stratified approach to targeting endocrine resistant breast cancer. 
 
Experimental Design 
Cell line and primary-derived xenograft models of endocrine resistance were investigated for 
susceptibility to TRAIL.  Tumour viability, cancer stem cell (CSC) viability (tumourspheres), 
tumour growth kinetics and metastatic burden were assessed.  Western blots for the TRAIL-
pathway inhibitor, c-FLIP, and upstream regulators were performed.  Results were 
confirmed in primary culture of 26 endocrine-resistant and endocrine-naïve breast tumours.   
 
Results 
Breast cancer cell lines with acquired resistance to tamoxifen-(TAMR) or faslodex were more 
sensitive to TRAIL than their endocrine-sensitive controls.  Moreover, TRAIL eliminated CSC-
like activity in TAMR cells, resulting in prolonged remission of xenografts in vivo. In primary 
culture, TRAIL significantly depleted CSCs in 85% endocrine-resistant, compared with 8% 
endocrine-naïve tumours, while systemic administration of TRAIL in endocrine-resistant 
patient-derived xenografts reduced tumour growth, CSC-like activity and metastases. 
Acquired TRAIL sensitivity correlated with a reduction in intra-cellular levels of c-FLIP, and an 
increase in Jnk-mediated phosphorylation of E3-ligase, ITCH, which degrades c-FLIP.  
 
Conclusions 
These results identify a novel mechanism of acquired vulnerability to an extrinsic cell death 





Current options for breast cancer patients who relapse on endocrine therapy are limited and 
mostly rely on re-targeting of endocrine pathways or non-specific chemotherapy, neither of 
which address the molecular changes that occur during transition to drug resistance. Here 
we identified one such acquired change, which resulted in endocrine-resistant tumours 
becoming sensitive to the pro-apoptotic effects of the targeted agent, TRAIL.   Moreover, 
this acquired sensitivity was particularly acute in the cancer stem-like cell population, 
leading to long-term regression of tumours in vivo.  Identification of the mechanism 
underlying this acquired sensitivity provides a companion predictive biomarker of this 
response.  This data supports future clinical investigation into the stratified use of TRAIL 
agonists for patients who develop resistance to endocrine-therapy, a key area of clinical 
unmet need that affects more than 8 million breast cancer patients worldwide. 
 
INTRODUCTION  
Over 70% of breast tumours express estrogen receptor (ER) and it is clear that estrogen itself 
plays a vital role in tumour development and progression (1). As a result, the non-steroidal 
anti-estrogen tamoxifen has provided improved survival and quality of life for many early 
and advanced ER+ve disease sufferers (2,3).  
Since the introduction of tamoxifen to the clinic nearly 30 years ago, further endocrine 
agents have been developed, notably the steroidal anti-estrogen fulvestrant (Faslodex) that 
also promotes estrogen receptor degradation (4), and aromatase inhibitors (AIs) that 
suppress estrogen production in the body (5,6). Although AIs are now the gold standard 
endocrine strategy in the ER+ve postmenopausal setting (7), tamoxifen remains a pivotal 
treatment option in ER+ve premenopausal breast cancer patients with 67% of patients 
responding to tamoxifen as first-line therapy (8–10). Fulvestrant in turn can prove valuable 
under conditions where tamoxifen or aromatase inhibitors fail (11).  
Unfortunately a large proportion of patients acquire resistance to endocrine treatment 
following initial responsiveness and this is associated with re-instigation of tumour growth 
and disease progression (12,13). Thus, the majority of patients with advanced disease and 
up to 30% of ER+ve patients in the adjuvant setting will acquire resistance to the inhibitory 
effects of their endocrine treatment (12,13). The acquisition of resistance manifests with a 
partial epithelial- mesenchymal transition and increased migratory and invasive activity both 
in anti-estrogen resistant cell line models (14) and in clinical samples (14–17). Furthermore, 
a subset of tumour-initiating cells with stem-like characteristics (cancer stem cells: CSCs) is 
enriched in tamoxifen-resistant breast cancers and may demonstrate resistance to 
endocrine therapies, thus contributing to disease recurrence and metastatic progression 
(18–21).  
It has been suggested that ER expression remains a stable phenotype for many acquired 
resistance tumours that initially respond to endocrine agents (22) which is corroborated by 
data showing that a significant proportion of acquired resistance tumours remain sensitive 
to alternative endocrine treatment. However, as a therapeutic avenue this too has its 
limitations, as response to additional endocrine therapies declines over time while some 
patients also lose ER expression during endocrine treatment (23–25). In vitro and xenograft 
model studies have elucidated that endocrine agents upregulate various “compensatory” 
growth factor signalling pathways that sustain cell survival and residual proliferative activity, 
culminating in resistant growth (26,27). A number of approaches have been examined in 
patients targeting such signalling mechanisms to overcome endocrine resistance (28), 
however, responses to such targeted approaches are short-lived for many patients (29,30). 
Of these agents, CDK4/6 (palbociclib, ribociclib) and mTOR inhibitors (everolimus) have 
shown particular promise, however, toxicities associated with these therapies must be 
managed carefully and predictive biomarkers for response are currently being investigated 
to help aid in patient selection (31–33). There thus remains a critical need for superior 
treatments guided by predictive biomarkers with greater long-term benefits in the 
management of endocrine resistance in the clinic. Tumour necrosis factor-Related Apoptosis 
Inducing Ligand (TRAIL) is an immune-related apoptotic protein that has been shown to 
specifically target cancer cells whilst sparing normal cells. Unfortunately, several studies 
have now shown that despite this cancer specificity, many tumour cell sub-types are 
inherently resistant to treatment with TRAIL agonists, with no improvement in overall 
survival rates in clinical trials (34). In breast cancer for example, epithelial-like ER-positive 
tumour cells are resistant to the pro-apoptotic effects of TRAIL, while cells with a 
mesenchymal phenotype, including CSCs within epithelial-like tumours, exhibit some 
sensitivity to TRAIL (35–37). Yet despite these observations TRAIL agonists have not 
progressed well in the clinical setting (34,38). Whilst tumour resistance has been largely 
attributed to poor agonist potency, it is probable that a scarcity of adequately stratified 
patient populations also partly contributes to resistance through a lack of understanding of 
the underlying mechanisms of resistance (39). The intrinsic TRAIL-mediated apoptosis 
inhibitor c-FLIP is believed to be one contributing factor behind TRAIL resistance of breast 
cancer cells as mesenchymal CSC and non-CSCs exhibit redistribution of c-FLIP (37) and 
removal of c-FLIP blockade hypersensitized both the bulk tumour cell population (40,41) and 
breast CSCs to TRAIL in vitro and significantly reduced metastasis in in vivo models (36).  
Given the evidence above that endocrine resistance was also associated with mesenchymal-
like traits (including CSCs), we postulated that endocrine-resistant breast tumours may 
respond better to TRAIL therapy than their endocrine naïve counterparts. If this were the 
case, we proposed that the increased TRAIL sensitivity may be mediated by c-FLIP. Here, we 
tested these hypotheses using in vitro and in vivo cell line models and clinical samples of 
acquired endocrine-resistant breast cancer. We showed that acquired endocrine-resistant 
breast cancer cell lines and their constituent CSC subpopulation were indeed sensitive to 
TRAIL treatment, and that this sensitivity correlated with the reduction of c-FLIP levels 
through a post-translational mechanism. Furthermore, the TRAIL-mediated reduction in 
endocrine-resistant CSCs in vitro was replicated in vivo with a marked reduction in 
metastatic disease. These findings were supported by patient-derived breast cancer tissue 
models leading to the conclusion that the selective use of TRAIL agonists to target the CSC 
compartment in breast tumours that have acquired endocrine resistance may improve 







 MATERIALS AND METHODS 
Cell Culture. Parental breast cancer cell lines MCF-7ER+HER2- and T47DER+HER2- (obtained 
from ATCC) were maintained in RPMI 1640 medium supplemented with 5% foetal bovine 
serum, 1% penicillin-streptomycin and 0.5% L-glutamine. Tamoxifen- and Faslodex-resistant 
sub-clones of these cell lines were derived as described (22,42,43) and maintained in phenol 
red-free RPMI 1640 supplemented with 5% foetal bovine serum (charcoal stripped for MCF-
7 derivatives) 1% penicillin-streptomycin, 0.5% L- glutamine and 100nM of 4-OH-tamoxifen 
(Sigma) or fulvestrant (AstraZeneca).  
siRNA. Small interfering RNAs (siRNA) targeting two unique sequences in human c-FLIP (FLIPi 
- Sense: GGAUAAAUCUGAUGUGUCCUCAUUA, Anti-Sense: 
UAAUGAGGACACAUCAGAUUUAUCC) and a non-specific scrambled control(SCi- Sense: 
GGACUAAUAGUUGUGCUCCAAUUUA, Anti-Sense: UAAAUUGGAGCACAACUAUUAGUCC) RNA 
were used in reverse transfections (Invitrogen). Cells were trypsinised and resuspended at a 
density of 1x105 cells/ml and seeded into wells containing 20μl of 100nM siRNA in serum 
free Optimem (GIBCO) in a volume of 100μl per well together with 0.3μl of Lipofectamine 
(Invitrogen). Cells were cultured in the presence of siRNA for 48 hours prior to subsequent 
assay.  
TRAIL Treatment of Target Cells. Cells were treated with soluble human recombinant TRAIL 
(SuperKillerTRAIL, Enzo Life Sciences) at a concentration of 20ng/ml or 100ng/ml for 18 
hours at 37oC in 5% CO2.  
Western blot assays. Western blots of cell lysates were performed as described (44). The 
following antibodies were used: c-FLIP (Enzo Life Sciences - 7F10, ALX-8040428, Santa Cruz – 
5D8, sc-136160), ER-alpha (Santa Cruz, sc-7207), ErbB2 (Abcam, ab2428), GAPDH (Santa 
Cruz, sc365062), ITCH (AbCam, 99087) and pITCH (Millipore, 10050).  
Cell viability and cell death assays. CellTiter blue cell viability assay (CTB) (Promega) was 
performed according to manufacturer’s instructions in a 96-well plate format and 
fluorescence assessed using a ClarioStar (BMG Labtech) plate reader, while Invitrogen 
live/dead labelled cells were stained for 15 minutes at 4oC in the dark and subsequently 
analysed by flow cytometry (BD Accuri).  
Primary-derived tumour cell processing and xenografts. Primary and local relapse human 
breast tumour pathological and post-surgical core biopsies were obtained following consent 
from the Cardiff and Vale Breast Cancer Centre, Llandough Hospital under NISCHR ethical 
approval (12/WA/0252) and pleural effusions/ ascitic fluid metastatic samples obtained 
through Manchester Cancer Research Center Biobank and The Christie NHS Foundation 
Trust (studies 12/ ROCL/01, 05/Q1402/25, respectively). Cells were processed, maintained 
and stored according to the Human Tissue Act with local (Cardiff University) research ethics 
approval. All animal xenograft procedures were performed in accordance with the Animals 
(Scientific Procedures) Act 1986 and approved by the UK Home Office (PPL 30/2849). 
Tumours excised from mice or received from patients were finely minced then processed in 
a MACs tissue dissociator using MACs tissue dissociation kit according to the manufacturers 
protocol (Miltenyi Biotec). Primary cells were maintained in 5% CO2, 5% O2 at 37
oC. The 
patient-derived xenograft (PDX) models were generated either as previously described (45) 
or for the PDX 151 model, 3mm chunks of primary tumour material from a 72 year old 
patient with local relapse previously receiving endocrine treatment (see supplementary 
figure 4A) were serially passaged by subcutaneous implantation in JAXTM NOD.Cg-
PrkdcscidIl2rgtm1Wj (NSG) mice.  
Tumoursphere culture. Cell lines and primary tumour samples were initially treated in 
adherent culture conditions as described then dissociated into single cell suspensions and 
plated (P1) in ultra-low attachment 96 well plates (Corning) at a density of 20,000 cells/ml in 
a serum-free epithelial growth medium (DMEM/F12, Gibco), supplemented with 2% B27 
(Invitrogen), 55 μM β-mercaptoethanol, 20ng/ml EGF (Sigma), 5μg/ml Insulin (Sigma) and 
1μg/ml hydrocortisone. After 7 days tumourspheres were collected by gentle centrifugation 
(300 x g), dissociated in 0.05% trypsin, 0.25% EDTA and re-seeded (P2) at 20,000 cells/ml for 
subsequent passages. %TFU was calculated by dividing the number of spheres formed by the 
total number of single cells seeded. 
Fluorescent activated cell sorting (FACS). The directly conjugated mouse FITC anti-CD24 
antibody (BD, 555427), mouse allophycocyanin (APC) anti-CD44 antibody (BD, 559942), 
mouse APC anti-DR5 (biolegend, DjR2-4), mouse FITC anti-DR4 (AbCam, ab59047) were used 
to stain single cell suspensions at 4oC in the dark for 30 minutes. Control samples were 
stained with isotype-matched control antibodies and samples analysed using BD Accuri flow 
cytometer.  
Aldefluor Assay. To measure ALDH activity, Aldefluor assay (Stem Cell Technologies) was 
performed on surviving cell populations as previously described (46). Briefly, dissociated 
single cells were suspended in assay buffer containing ALDH substrate, 
bodipyaminoacetaldehyde (BAAA) at 1.5 mM, and incubated for 45 min at 37oC. To 
distinguish between ALDH+ve and –ve cells, cells were also incubated under identical 
conditions in the presence of a 2-fold molar excess of the ALDH inhibitor, 
diethylaminobenzaldehyde (DEAB).  
Xenograft assays of MCF-7-TAMR cells. Tumour initiation and growth was assessed by 
orthotopic mammary fat pad transplantation of dissociated MCF-7 and MCF-7-TAMR cells. 
Cells were harvested using 1mM EDTA, washed and resuspended at a density of 5x106 
cells/ml in serum-free L15 media. A 1.5mg, 90-day slow release 17-β estradiol or Tamoxifen 
pellet (Innovative Research of America, Sarasota FLA) for parental and TAMR cells 
respectively was inserted subcutaneously above the right scapula of anaesthetised NOD-
SCID mice (Harlan). 1x106 cells were orthotopically injected directly into the abdominal 
mammary fat pad and when tumours reached 5mm in diameter the mice were treated with 
16mg/kg TRAIL (IP) daily for 4 days twice, separated by a 6 day treatment holiday. Mice were 
then monitored and tumour volume measured twice weekly. Metastatic tumour burden 
within lung tissue was then assessed histologically in serial H&E sections.  
RNA extraction and cDNA synthesis. Cultured cells were pelleted via centrifuge at 300rcf for 
5 min before being resuspended in 350 µL RLT buffer (Qiagen) and placed on ice for 
immediate extraction or frozen at -80oC for future extraction. RNA extraction was performed 
using the Qiagen RNEasy kit following the manufacturer’s instructions. The concentration 
and quality of RNA was analysed using a nanodrop 3000 spectrophotometer (Thermo 
Scientific). Previously isolated RNA was synthesized into cDNA using the QuantiTect Reverse 
Transcription kit (Qiagen) according to manufacturer’s instructions. 
 
Quantitative PCR (QPCR). All qRT-PCR experiments were designed to include both target 
gene probes and ACTB control probe. For each experiment TaqMan Universal Master Mix II, 
with UNG (ThermoFischer Scientific) was used. TaqMan master mix was added to target and 
ACTB control probes together with RNase free H2O to make individual target master mixes 
containing all reaction components and plated in 384-well qPCR plates (Applied Biosystems). 
Plates were then run on a QuantStudio 7 Real-Time PCR machine (Applied Biosystems) set to 
the following protocol: initial denaturation at 95oC for 10 min, followed by 40 cycles of 95oC 
for 15 sec (denaturation), and 60oC for 1 min (annealing/elongation). Relative quantity (RQ) 
was determined using  ΔΔCt values calculated from the reference sample. 
 
Statistical methods. Data are represented as mean +/- standard error of the mean for a 
minimum of three independent experiments, unless otherwise stated. Statistical significance 
between means was measured using parametric testing, assuming equal variance, by 
standard T-test for two paired samples. The chi-squared test was used to determine the 




Acquired endocrine-resistant breast cancer cell lines develop hypersensitivity to TRAIL-
induced cell death. The development of endocrine therapy resistance in primary breast 
cancer is associated with poor prognosis and, in cell line models and clinical samples of 
endocrine resistance, by a transition to more aggressive tumour phenotypes that have 
undergone partial EMT (14–17). The cancer therapeutic TRAIL has been shown to 
preferentially induce cell death in breast cancer cell lines that exhibit a more mesenchymal 
phenotype (35). We wished to investigate therefore whether the adaptation to endocrine 
treatment also increased the sensitivity of breast cancer cells to TRAIL. Initially 4 models of 
acquired endocrine-resistance, derived from continuous endocrine treatment with 
tamoxifen or Faslodex of the luminal ER+ve breast cancer cell lines MCF-7 (42) and T47D (43) 
were investigated. Acquired tamoxifen-resistant (TAMR) and acquired Faslodex-resistant 
(FASR) cell lines were significantly more sensitive to the cytotoxic effects of TRAIL than their 
parental controls. (Figure 1A, B and Figure S1A). Sensitivity was particularly prominent in the 
TAMR derivatives. The gain in TRAIL sensitivity was then confirmed in an independent MCF-
7-derived tamoxifen-resistant model (20) (Figure S1B). This marked susceptibility to TRAIL 
could not be explained by the combinatorial effect of TRAIL with either endocrine agent and 
was a feature confined to the resistant state, as the combination of tamoxifen or Faslodex 
with TRAIL treatment on the previously untreated MCF-7 cells (co-treated) or on cells pre-
treated with these endocrine agents for up to 7 days (pre- treatment) did not confer TRAIL 
sensitivity (Figure 1C). Furthermore, tamoxifen withdrawal (TAMR-W) for 7 days prior TRAIL 
treatment also had no effect on the sensitivity of TAMR cells to TRAIL (Figure 1D). 
Combined, these results suggested that the substantially-increased TAMR sensitivity to 
TRAIL was due to a stable adaptation resulting from acquired resistance to tamoxifen.  
  
TRAIL treatment of acquired endocrine-resistant cells targets cancer stem cell- like traits in 
vitro According to the cancer stem cell hypothesis, a drug resistant sub-population of 
stem/progenitor-like tumour cells is likely to contribute to promotion of resistance to 
conventional therapies (18,21,47,48). To determine if these cells demonstrated a 
comparable sensitivity to TRAIL to the bulk cell cultures in the acquired endocrine-resistant 
lines, the effect of TRAIL on stem-like activity was assessed by tumoursphere assay while 
cancer stem/progenitor-cell numbers were measured using cell surface markers and 
ALDEFLUORTM assay. Both the MCF-7-derived TAMR and FASR cell lines exhibited an 
increased capacity to form tumourspheres, that were similar in morphology and size to their 
parental MCF-7 cell line. However, in contrast to the parental line, these self-renewing 
tumoursphere-forming cells were significantly more sensitive to TRAIL, with a complete 
ablation of tumoursphere forming units (TFU) and colony forming units (CFU) in the TAMR 
cells following treatment with TRAIL (Figure 2A & 2B, Figure S2C). Furthermore, this TRAIL 
sensitivity was independent of the presence of tamoxifen in the media (Figure 2C), implying 
that the hyper-sensitization to TRAIL was inherent to the acquired endocrine (tamoxifen) 
resistance phenotype. The effect of TRAIL on the cancer stem cell compartment in the 
TAMR line was further supported by flow cytometry using surrogate markers of 
stem/progenitor cells. Both CD44HiCD24Lo and ALDH+ve sub-populations were significantly 
elevated in tamoxifen-resistant cell lines yet remained sensitive to TRAIL-mediated 
apoptosis (Figure 2D), although TRAIL failed to further deplete the CD44 population in TAMR 
cells. A significant reduction in CSC-like activity was also observed in a second cell line model 
of acquired tamoxifen resistance (T47D-derived), although the sensitivity to TRAIL was not 
as profound, TRAIL treated TAMR cells were still significantly reduced compared to their 
TRAIL-treated parental counterparts (Figure S2A & S2B) with a 50% reduction in 
tumoursphere forming capacity and a 4-fold reduction in CD44+ve cells in T47D-TAMR cells 
following TRAIL treatment. In summary, this data suggests that sensitivity of breast cancer 
stem-like cells to TRAIL develops following the acquisition of resistance to anti-estrogens, 
most acutely with tamoxifen resistance.  
Systemic TRAIL administration results in long-term regression of TAMR tumours in vivo In 
order to determine if the TRAIL-mediated reduction in overall cell viability and CSC-like 
properties in vitro was reflected in tumour growth in vivo, mice bearing established MCF-7 
parental or TAMR orthotopic tumours of approximately 5mm in diameter were subjected to 
eight intraperitoneal injections of TRAIL over a period of 2 weeks, then monitored for 
tumour response. Along with the previously observed elevation in CSC-like and proliferative 
activity of TAMR cells in vitro (Figure 2B), orthotopic TAMR tumours were found to be more 
aggressive than parental MCF-7 controls under vehicle control conditions, with an elevated 
growth rate and appearance of spontaneous metastases to the lung (Figure 2E, F). MCF-7 
tumours responded transiently to TRAIL treatment (20% reduction in tumour volume) but 
within two weeks of treatment, had regained similar growth kinetics to the vehicle treated 
cohort (Figure 2E). Treatment of TAMR tumours with TRAIL on the other hand resulted in a 
complete (100%) and sustained regression of all tumours (n=8) for up to 15 weeks (Figure 
2E). Furthermore, following TRAIL treatment both the number and size of TAMR metastatic 
lesions in the lungs were decreased by more than 95% (Figure 2F), correlating with the 
profound decrease in CSC-like activity observed in vitro (Figure 2B). Taken together these 
data suggested that tamoxifen-resistant cell response to TRAIL in vivo correlated with the 
observed in vitro responses whereby tumour regression occured by de-bulking tumour mass 
and in turn metastatic tumour burden and tumour relapse were significantly reduced 
through the elimination of the cancer stem/progenitor pool.  
Clinical samples from multiple endocrine drug-resistant patients exhibit TRAIL sensitivity. 
Having seen clear benefits of TRAIL treatment in cell line models of anti- estrogen-resistance 
in vitro and in vivo, the efficacy of TRAIL on endocrine-resistant breast cancer was 
determined in clinical samples ex vivo. Primary cell cultures were derived from pleural 
effusions or ascites of 13 patients with advanced ER+ve breast cancer, 11 having received 
endocrine treatment and 2 endocrine-naïve samples (Figure S3A). Cells were plated into 
tumoursphere culture prior to treatment with TRAIL ex vivo (Figure 3A). 9 out of 11 (82%) of 
the clinical samples from the advanced metastatic endocrine-resistant patients exhibited a 
significant reduction in tumoursphere forming units (TFU) following treatment with TRAIL 
(Figure 3A) while neither of the endocrine-naïve metastatic patient samples (90 and 94) 
responded to TRAIL. Similarly, 7 out of 8 (88%) of the endocrine-resistant patient samples 
cultured as an adherent monolayer were also sensitive to TRAIL, with only one of the two 
endocrine-naive samples exhibiting a significant response to TRAIL (Figure S3B).  
A similar relationship was observed in primary cell cultures derived from 13 fresh core 
biopsies of local relapse ER-positive breast cancer (Figure 3A). Of two tumour biopsies 
originating from patients who had relapsed following treatment with tamoxifen (samples 
127 and 188) both demonstrated a significant reduction in tumoursphere forming capacity, 
while only 1 of 11 (9%) of endocrine treatment-naïve primary tumours exhibited such a 
response to TRAIL.  
Overall, 11 of 13 samples (85%) from all clinical groups that had relapsed following 
endocrine treatment responded to TRAIL ex vivo, compared to just 1 of 13 tumours that had 
not previously seen endocrine therapy (Figure 3A, B & C). Taken together, the findings from 
these ex vivo models provide pre-clinical evidence that TRAIL may be valuable in controlling 
endocrine-resistant breast cancers and potentially provide long-term benefits by targeting 
the CSC subset.  
In vivo PDX models of endocrine-resistant breast cancer demonstrate sensitivity to TRAIL 
administration. The potential for TRAIL as a further therapeutic option following acquisition 
of endocrine resistance was subsequently tested in vivo using two distinct patient-derived 
xenograft (PDX) models of endocrine-resistant breast cancer.  
For the first PDX model, a primary ER-positive tumour was maintained orthotopically by 
serially passaging in immunocompromised mice receiving either estradiol (MaCa 3366) or 
tamoxifen (MaCa 3366 TAMR) for up to 3 years, generating estradiol-dependent and 
tamoxifen-resistant models respectively from the same parental tumour tissue (45). Mice 
were subjected to systemic administration of 8 intraperitoneal injections of TRAIL over 2 
weeks (treatment windows highlighted in pink, Figure 4) and tumour growth kinetics 
monitored from the beginning of treatment (100mm3). In the tamoxifen-sensitive estrogen-
dependent control tumours, systemic in vivo TRAIL treatment failed to elicit a significant 
growth inhibitory response compared with vehicle only (Figure 4A). There was also no 
alteration in the CSC compartment within the tumours (Figure 4A). In contrast, a transient 
(10 day) yet significant regression of MaCa 3366 TAMR tumours was observed following first 
TRAIL administration, compared to a doubling in tumour volume in the vehicle control arm 
over the same time period, which after a second dose of TRAIL culminated in a sustained 
and significant reduction in tumour size at 4 weeks compared to untreated controls 
(p=0.0045) (Figure 4B). Thus while TRAIL-treated naïve 3366 tumours exhibited a 4-fold 
increase in tumour volume over 4 weeks, TRAIL treated endocrine-resistant tumours 
exhibited a 1.8-fold increase over the same time period (Figure 4A & 4B). Furthermore, 
consistent with observations in our cell line models of tamoxifen resistance there was a 
significantly higher basal level of CSC- like cells in MaCa 3366 TAMR tumours compared with 
its endocrine responsive, estrogen-dependent, counterpart, and TRAIL treatment in vivo 
significantly depleted the CSC-like activity in the tamoxifen-resistant model (Figure 4B) 
whereas no significant difference was observed in the endocrine-sensitive model. 
Additionally, tumourspheres generated from the TRAIL-treated MaCa 3366-TAMR tumours 
also maintained their sensitivity to TRAIL when treated ex vivo, demonstrating that the 
tumoursphere-forming subset surviving in vivo TRAIL administration was not a consequence 
of acquired TRAIL resistance (Figure S4B).  
For the second PDX model, a core biopsy (CUbbs 151) obtained from a locally relapsed ER- 
negative tumour from an ER-positive (original status prior to endocrine treatment) breast 
cancer patient who had relapsed on the aromatase inhibitor (AI) anastrazole, was used to 
propagate tumours in recipient immunocompromised mice to model AI-resistant breast 
cancer (histopathologically characterised in Figure S4A). AIs have become the gold standard 
first-line therapy for the majority of postmenopausal ER-positive breast cancer patients, and 
many of the endocrine-resistant clinical samples used in this study (Figure 3) had at some 
point in their treatment received an AI (Figure S3A). In order to determine AI- resistant 
breast cancer sensitivity to TRAIL, mice bearing CUbbs 151 tumours (PDX 151) were 
administrated 8 intraperitoneal injections of TRAIL over 2 weeks. This resulted in a 
significant reduction in AI-resistant tumour growth compared to vehicle control (Figure 4C) 
and ex vivo control PDX 151 tumour cells also demonstrated significant sensitivity of CSC-like 
cells to treatment with TRAIL (Figure 4D). Furthermore, the sensitivity of PDX 151 CSCs ex 
vivo was consistent with the sensitivity of the patient biopsy (CUbbs 151) treated ex vivo 
prior to transplantation (i.e. original biopsy straight from the patient) (Figure S4C). This was 
paralleled by a profound reduction in both the number and size of spontaneous lung 
metastases in vivo (Figure 4E) adding additional confirmation that the CSC-like compartment 
within these tumours was particularly sensitive to TRAIL treatment.  
c-FLIP degradation via Jnk activation leads to the observed sensitivity of tamoxifen-
resistant breast cancer cells In order to elucidate the underlying cause of the TRAIL 
hypersensitivity gained both in endocrine-resistant breast cancer cell lines and clinical 
tumours, key cellular components of TRAIL-mediated cytotoxicity were assessed by western 
blot and FACS analysis in the TAMR and FASR cell lines. These included the TRAIL receptors 
DR4 and DR5 and the endogenous TRAIL-receptor complex inhibitor c-FLIP, all of which have 
been shown to influence TRAIL sensitivity in other cancer cell types (49–52). Comparative 
levels of DR4 and DR5 cell surface receptor expression did not reflect the relative sensitivity 
of each cell line to TRAIL (Figure S5A). The relative protein levels of the TRAIL pathway 
inhibitor, c-FLIP (55kDa isoform identified with two independent antibodies), however, were 
found to be lower in TAMR cells compared to parental MCF-7 cells (Figure 5A). Similarly, c-
FLIP protein levels were also significantly reduced in TAMR and FASR derivatives of the T47D 
cell line (Figure 5A). This reduction in c-FLIP protein levels is attributed to post-transcription 
regulation of c-FLIP, as no correlation between c-FLIP mRNA levels in either the cell lines or 
the primary samples tested correlated with TRAIL response (Figure S5B).  
Previously a Jnk-mediated degradation of c-FLIP via the E3 ubiquitin ligase ITCH has been 
described to explain regulation of c-FLIP protein in primary mouse cells (53)(Figure S5C). 
Accordingly, phosphorylated ITCH (pITCH) was upregulated in MCF-7 and T47D- derived 
TAMR and FASR cells (Figure 5A) compared to parental controls with no parallel increase in 
total ITCH levels. The proposed link between Jnk and suppressed c-FLIP levels was confirmed 
by pre-treatment of the MCF-7-derived TAMR cells with the Jnk inhibitor SP600125 which 
after 4 hour exposure partially rescued TAMR cell and endocrine-resistant primary sample 
viability in the presence of TRAIL (Figure 5B, Figure S5D and Figure S5E). Furthermore, Jnk 
inhibition decreased ITCH activation (reduced phospho-ITCH levels) and subsequently 
restored c- FLIP protein expression of TAMR cells to parental MCF-7 levels (Figure 5C). 
Similarly, untreated MaCa 3366-TAMR tumours exhibited a significantly lower level of c-FLIP 
protein expression and increased ITCH and pITCH expression compared to its endocrine 
sensitive, estrogen-dependent control (Figure 5D). Western blot analysis of 8 of the 
advanced metastatic endocrine-resistant clinical samples ex vivo with varying TRAIL 
response was performed in order to determine if the mechanism of sensitivity in these 
primary cells was consistent with that of the endocrine-resistant cell lines (Figure 5E). The 
activation (phosphorylation) of ITCH and relative c-FLIP levels were subsequently 
determined by densitometry normalised to GAPDH controls. The activation of ITCH and c-
FLIP protein levels were inversely correlated such that increased activation of ITCH in 
endocrine-resistant samples correlated with a reduction in c-FLIP levels and, when averaged, 
cells sensitive to TRAIL had significantly lower levels of c-FLIP and higher levels of ITCH 
activation (Figure 5F, Figure S5F). Additionally, reduction of c-FLIP protein levels and 
increased ITCH activation correlated with response to TRAIL (Figure 5F, Figure S3B). 
Furthermore, the advanced metastatic endocrine-resistant clinical sample with the lowest 
activation of ITCH (sample 81, Figure 5E) and the sample with the highest level of c-FLIP 
protein (sample 29, Figure 5E), both of which demonstrated no significant response to TRAIL 
under adherent conditions, could be substantially sensitised to TRAIL by siRNA inhibition of 
c-FLIP, supporting the role for c-FLIP in TRAIL sensitivity (Figure 5G, Figure S5G and S5H). 
Finally, the endocrine-naïve, TRAIL-resistant, clinical sample 90, could also be sensitised to 
TRAIL by siRNA suppression of c-FLIP (Figure 5H, Figure S5I). These data demonstrate that 
the activation of ITCH and reduction of c-FLIP is one potential mechanism of hypersensitivity 
of endocrine-resistant clinical samples ex vivo.  
DISCUSSION  
There is a clear unmet need for alternative treatments for patients who relapse on 
endocrine therapy. Relapse rates are high and following multiple lines of endocrine therapy 
there is higher risk of metastasis and poorer overall survival with limited treatment options.  
Here we demonstrate that acquired endocrine-resistant breast cancer cells gain sensitivity 
to TRAIL treatment compared with their endocrine responsive parental counterparts. This 
appears to manifest following the acquisition of resistance and is a stable sensitivity, as 
administration of endocrine agents in ER-responsive cells does not increase response to 
TRAIL.  
Although other changes in signalling pathways have been identified as a consequence of 
endocrine-resistance – such as EGFR/HER2, MAPK, CDK4/6, mTOR and Src (54–59) – the data 
reported here represents to our knowledge the first demonstration of a sensitization to a 
single agent targeting a pro-apoptotic pathway. Previous studies have demonstrated 
increased Jnk signalling following the long-term acquisition of resistance to endocrine 
therapies (12,60). Here we demonstrate that one consequence of this Jnk activation is the 
ITCH-dependent destabilisation of c-FLIP protein, which correlates with TRAIL sensitivity 
both in cell line models in vitro and in clinical samples ex vivo.  
Previously, modest outcomes in phase II clinical trials of TRAIL agonists in terms of overall 
survival has been partly attributed to the lack of potency of existing TRAIL receptor agonists 
(34), however, it could also be postulated that a lack of stratification and suitable 
biomarkers for response also contribute to the poor results seen to date. The data 
presented here suggests that acquired resistance to endocrine therapy, could represent a 
key subgroup of patients that might exhibit improved responses to TRAIL agonists and that 
monitoring of c-FLIP, pITCH and/or p-Jnk levels in tumours could further potentiate the 
selection process by identifying at least a proportion of TRAIL-responsive tumours. Further 
exploration of these molecular markers by immunohistochemical analysis of pathological 
samples with access to fresh tissue material would be required to determine if these could 
be used as predictive biomarkers of TRAIL response.  
We recently reported that TRAIL can selectively target the CSC-like cells in breast cancer cell 
lines in vitro following suppression of c-FLIP. Here we demonstrate that acquired endocrine 
resistance potentiates sensitivity of the CSC-like compartment to TRAIL in primary-derived 
breast cancer samples, and that this significantly correlates with a reduction in c-FLIP levels. 
These observations are particularly significant given that CSCs have been demonstrated to 
evade conventional chemotherapy agents and potentially endocrine agents, either due to 
cell quiescence, through the prevention of drug uptake or modulation of intracellular 
signalling (18,21,61–63). Targeted therapies that initiate cell death through cell surface 
receptors circumvent these resistance mechanisms and therefore may prove to be a more 
effective strategy for targeting CSCs (64–66). Indeed, this was confirmed in xenograft models 
of endocrine-resistant tumours, whereby systemic TRAIL treatment resulted in a profound 
suppression of tumour recurrence (Figures 2 & 4) and a marked decrease in spontaneous 
metastasis (Figures 2F & 4E). Interestingly, response to TRAIL was observed regardless of 
cellular ER status. In vitro models of TAMR maintain ER-positivity following acquisition of 
resistance and active ER signalling remains important in cell proliferation. Similarly, MaCa 
3366 also maintains ER positivity following acquisition of resistance, however, FASR cell lines 
and PDX 151 do not maintain their ER positivity. Despite these important differences in 
cellular signalling, all these models demonstrated sensitivity to TRAIL treatment in vitro and 
in vivo. Taken together, these data have important implications for potential long-term 
survival benefit patients who ultimately relapse on any form of endocrine therapy.  
Previous studies have proposed that the acquisition of endocrine resistance is accompanied 
by the appearance of mesenchymal-like properties, which might also explain the increased 
risk of metastatic disease. This was the premise on which we initially tested for TRAIL 
sensitivity in endocrine-resistant breast cancer cells, as TRAIL had previously been shown to 
selectively target breast cancer cell types with a mesenchymal-like phenotype (35). The 
question still remains as to whether a partial epithelial-mesenchymal transition sufficiently 
explains the strong correlation between endocrine resistance and TRAIL sensitivity in clinical 
samples observed here. Further studies into the mechanism of Jnk activation and the role of 
EMT-like processes in TRAIL sensitivity will help elucidate its relationship with acquired 
endocrine resistance.  
In summary, we have shown that acquired endocrine resistance confers sensitivity of breast 
cancer cells and particularly breast cancer stem cells to TRAIL-mediated apoptosis. These 
data support further investigation into the selective use of TRAIL agonists as a subsequent 
treatment for ER+ve patients who relapse on endocrine therapy regardless of their ER status 
following relapse.  
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Figure 1: Acquisition of endocrine resistance in breast cancer lines confers sensitivity to 
TRAIL. A) Acquired endocrine (faslodex or tamoxifen) resistant MCF-7 and B) T47D cell lines 
together with their parental endocrine responsive lines were treated with 20ng/ml TRAIL for 
18 hours and viability assessed by CTB assay relative to their respective untreated control 
(*p <0.01). C) MCF-7 cells were either co-treated with endocrine treatment (100nM 
tamoxifen or faslodex) plus 20ng/ml TRAIL for 18 hours, or pre- treated for 7 days with 
endocrine agent and TRAIL for 18 hours, and viability was assessed by CTB assay (*p <0.01). 
D) MCF-7 TAMR cells were cultured as normal or with tamoxifen withdrawn for 7 days 
(TAMR-W) prior to 20ng/ml or 50ng/ml TRAIL treatment for 18 hours and viability assessed 
by CTB assay (*p<0.01).  
 
Figure 2: CSCs in MCF-7-derived endocrine-resistant lines demonstrate hypersensitivity to 
TRAIL. A) Representative tumourspheres formed from surviving cell population following 
20ng/ml TRAIL treatment for 18 hours. B) MCF-7 cells and their derived endocrine-resistant 
lines were treated with TRAIL or vehicle for 18 hrs in adherent culture, before transferring to 
tumoursphere culture conditions for one week and colonies counted as a % of viable cells 
seeded (*p<0.03, **p<0.01). C) MCF-7 TAMR cells previously maintained in adherent culture 
with tamoxifen or tamoxifen withdrawn (TAMR-W) for 1 week and then treated with 
20ng/ml TRAIL for 18 hours were transferred to tumoursphere assay as above (*p<0.01). D) 
Expression of CSC surrogate markers (CD44, CD24, ALDH) in the MCF-7 parental and TAMR 
cell lines following 18 hours TRAIL treatment compared with their respective untreated 
control (*p<0.01). E) 107 MCF-7 parental or TAMR cells were transplanted into the 4th 
inguinal mammary gland and 16mg/kg TRAIL administered 8 times over 2 weeks (4 x daily, 6 
days treatment holiday then 4 x daily) once tumours had reached a volume of 100mm3 and 
growth kinetics monitored following final treatment by caliper measurement relative to 
starting tumour volume (*p<0.03, ***p<0.001 n=8 per group). F) Lung metastatic burden in 
vehicle or TRAIL treated TAMR transplanted animals following sacrifice at week 16 (*p<0.03, 
**p<0.01). 
 
Figure 3: Endocrine-resistant clinical relapse tumour samples display increased 
tumoursphere sensitivity to TRAIL compared to endocrine-naïve samples. A) 
Tumourspheres isolated from anti-estrogen (AE)-resistant metastatic BC (red hashed), 
endocrine resistant local BC (red), endocrine-naïve metastatic BC (white hashed) and 
endocrine naïve local BC were treated with 100ng/ml TRAIL for 18 hours and fold change in 
%TFU from paired untreated control calculated for each sample 2 weeks later *p<0.05 vs 
paired control. B) Mean endocrine-naïve BC sample (metastatic and local combined) and 
endocrine-resistant (metastatic and local combined) %TFU following TRAIL treatment 
compared to their untreated controls (*p<0.01, n=13). C) Comparison of mean TRAIL 
response in endocrine naïve and resistant samples (* p<0.03, n=13). 
 
Figure 4: Endocrine-resistant PDX models of BC demonstrate sensitivity to TRAIL. A) 
Established Tamoxifen-sensitive and B) Acquired Tamoxifen- resistant MaCa 3366 PDX 
tumours (n=8 each) were treated 8 times in 2 weeks with 16mg/kg of TRAIL I.P (pink = 4 x 
daily treatment windows) and growth kinetics monitored weekly by caliper measurement 
compared with vehicle control (* p<0.03, n=8). Vehicle and TRAIL- treated tumours excised 
24 hours following the final TRAIL administration were dissociated and tumoursphere 
forming capacity assessed (P1). TFUs were then disaggregated and passaged to assess self-
renewal capacity (P2) (* p<0.03, n=3) C) AI-resistant PDX model of BC (PDX 151) was treated 
and monitored as in (A) and tumour growth kinetics monitored by caliper measurement 
(p<0.03, n=3). D) Vehicle control PDX 151 AI-resistant tumours were excised, dissociated and 
%TFU assessed following treatment with 100ng/ml TRAIL for 18 hours ex vivo (*p<0.03). E) 
Assessment of lung metastatic burden (mean number and size of metastasis +/- SEM) in H+E 
serial sections from vehicle control and TRAIL treated PDX 151 tumours 2 weeks following 
last TRAIL treatment (* p<0.03). 
 
Figure 5: Endocrine-resistant breast cancer cell sensitivity to TRAIL correlates with inherent 
increased ITCH activation (via Jnk activation) and c-FLIP protein reduction. A) Pan-ITCH 
phosphorylated-ITCH, and c-FLIP (long, 55kDa) protein levels in endocrine-resistant MCF-7 and 
T47D cell lines as assessed by western blot versus parental control. Two antibodies to the long 
form of cFLIP are used in MCF-7 cells to confirm specificity.  B) MCF-7 TAMR cells and primary 
endocrine-resistant BB3RC46 cells were incubated with or without 10µM SP600125 Jnk inhibitor 
(JNKi) for 4 hours and then treated with or without 20ng/ml (TAMR)/ 100ng/ml (BB3RC46) TRAIL 
for 18 hours and mean cell viability/cell death was assessed by CTB (*p<0.03, n=3). C) MCF-7 
TAMR cells were incubated with or without JNKi for up to 4 hours and ITCH, pITCH and c-FLIP 
protein levels assessed by western blot. D). Levels of ITCH expression/activation and c-FLIP 
protein were assessed by western blotting protein extracted from MaCa 3366 (A6 and A7) and 
MaCa 3366 TAMR tumours (A1 and A6). E) ITCH activation and c-FLIP protein levels in endocrine-
resistant metastatic tumour samples as determined by western blot. F) Correlation of c-FLIP 
protein level and ITCH activation to each other and to sample response to TRAIL (from Figure 
S3B). G) A TRAIL-resistant, endocrine-resistant, clinical sample from a metastatic breast cancer 
patient, BB3RC81, was incubated with either scrambled control (SCi) or FLIP targeted (FTi) siRNA 
and then treated with 100ng/ml TRAIL for 18 hours and cell viability assessed by CTB (**p<0.01). 
H) A TRAIL-resistant, endocrine-naïve, clinical sample from a metastatic breast cancer patient, 
BB3RC90, was incubated with either scrambled control (SCi) or FLIP targeted (FTi) siRNA and 
then treated with 100ng/ml TRAIL for 18 hours and cell viability assessed by CTB (**p<0.01). 
 
